Key result
Valaciclovir and immunoglobulin therapy linked to fetal CMV brain lesion progression in only ~13% of cases.
Why the study?
Valaciclovir and immunoglobulin have shown relative success separately for fetal CMV infection, but there was no experience with their simultaneous use.
Does combination therapy with valaciclovir and immunoglobulin improve fetal outcomes in pregnant women with high-risk CMV infection?
Population
15 pregnant women with CMV infection and amniotic fluid VL above 105 copies/ml or fetal brain injuries
Comparison
Combination therapy with oral valaciclovir and intravenous hyperimmune gamma globulin
Follow-up
At birth and every 3 months during follow-up
Authors
Loading...
May support combination therapy in select high-risk fetal CMV; leaves open efficacy without controlled trials.
Observational (n=15)
Does combination therapy with valaciclovir and immunoglobulin improve fetal outcomes in pregnant women with high-risk CMV infection?
Combination therapy with valaciclovir and immunoglobulin appears safe and may be a useful alternative for fetal CMV infection with high viral load or cerebral echography changes.
Calle et al. (2020) conducted an observational in Cytomegalovirus (CMV) infection during pregnancy with high risk of symptomatic fetal disease (n=15). Combination therapy with immunoglobulin and valaciclovir was evaluated. In 15 pregnant women with fetal CMV infection, combination therapy with immunoglobulin and valaciclovir limited fetal brain lesion progression to 2 cases and hearing impairment to 3 cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: